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In the cardiovascular system, NO plays integral roles not only in the regulation of vascular smooth muscle tone but also in the function of ion channels, myocyte contraction, O 2 consumption, apoptosis, and hypertrophic myocardial remodeling (36, 92) . In cardiac endothelial cells and myocytes, NO is generated by NO synthase (NOS) isozymes: neuronal NOS (nNOS or NOS1), inducible NOS (iNOS or NOS2), and endothelial NOS (eNOS or NOS3) (71, 75) . Initially, eNOS was considered to be the only isoform constitutively expressed in myocytes and thus the source of NO involved in the autocrine regulation of myocardial contraction and Ca 2ϩ homeostasis (7, 37) . However, subsequent studies showed that NOS is targeted to the cardiac sarcoplasmic reticulum (SR) (137) and localized in cardiac mitochondria (72) . Additionally, iNOS has been shown to be expressed in the myocardium upon induction by cytokines (8) during inflammatory responses implicated in many pathophysiological conditions. There is growing evidence supporting the initial reports on the existence of a mitochondrial NOS (mtNOS) (54, 58) and the involvement of mitochondrial NO in the regulation of cellular functions. Nevertheless, some studies failed to show heart mitochondrial NO production, and the evidence about lack of existence of mtNOS within the heart and the liver has been published by these authors (21, 32, 82, 124) . Interestingly, the detection limitation of the assays used in these studies has been reviewed and alternative methods have been suggested (53) .
Although NO is highly diffusible, signaling functions of this molecule produced by specific NOS isoforms seem to be compartmentalized in distinct cellular microdomains and to modulate cardiac function differently. This article reviews the evidence about the NOS activity in heart mitochondria and about the impact of mtNOS in cardiac function under physiological and pathological conditions.
Biochemistry of NO in the Heart
The effects of NO in the heart stem from its production within different cellular compartments and its interactions with several biomolecules involved in distinct downstream signaling pathways. It is well known that NO activates soluble guanylate cyclase by binding reversibly to the heme iron of soluble guanylate cyclase and by forming a Fe-nitrosyl complex with the enzyme (134) . This activation leads to the production of 3=,5=-cyclic guanosine monophosphate (cGMP) that stimulates protein kinase G and cGMP-regulated phosphodiesterases activities (83) .
Certain key functions of NO in signaling and regulation of cardiac function are performed through cGMP-independent pathways including those that involve mitochondria (104) . At physiological submicromolar concentrations, most distinct effects of NO on mitochondria are exerted on the respiratory chain. First, NO competes with O 2 for the binding site at the binuclear center of cytochrome c oxidoreductase. This leads to a high affinity and reversible inhibition of cytochrome c oxidase activity (24, 26) . A second important effect of NO on mitochondrial respiratory chain is accomplished through the reaction of NO with the respiratory complex III, ubiquinolcytochrome c oxidase. The exact mechanism underlying this effect in not fully understood. However, it has been shown that interaction of NO with mitochondrial respiratory complex III inhibits the electron transfer and enhances the production of superoxide anion (O 2 Ϫ ) (108, 109, 127) . In the matrix, the manganese superoxide dismutase catalyzes the reaction of two molecules of O 2 Ϫ to form hydrogen peroxide (H 2 O 2 ), an uncharged species involved in the control of cell proliferation and death (51) .
Other effects of NO in cell signaling are conveyed via nitrosation of proteins (121, 123) . In nitrosation reactions, NO reacts reversibly with the nucleophilic centers in thiol residues contained within a specific consensus sequence of amino acids (123, 135) of a broad array of low molecular weight compounds (117) or proteins (120) . When mitochondria are treated with NO donors, complex I is S-nitrosated resulting in significant inhibition of this respiratory complex (14, 25) .
NO also reacts with O 2 Ϫ that is formed by the mitochondrial respiratory chain during normal or pathological oxygen metabolism. This reaction occurs at a rate constant of about 2 ϫ 10 10 M Ϫ1 ·s Ϫ1 , and its velocity is controlled by the diffusion rate of the reactants (77) . The product is peroxynitrite (ONOO Ϫ ), a nonradical species capable of oxidizing and nitrating biomolecules and damaging irreversibly those targets (112) . This NO congener may hinder mitochondrial functions and cause cell death. ONOO Ϫ also influences cardiac contractility and, in some cases, produces effects that are markedly different from those of NO (74, 93) . Diverse factors participate in the switch from reversible inhibition of cellular respiration by NO to the pathological inhibition of mitochondrial function by ONOO Ϫ . Distinct features of mitochondria make the organelles particularly important targets for biological effects of NO.
Heart NOSs
In the heart, specific NOS isoforms are distinctly located in cardiomyocytes (63, 144) , and such compartmentalization provides a unique condition whereby the enzyme produces NO nearby target effectors within the same subcellular region (Fig. 1) . While NO is highly diffusible, the distances that this free radical effectively travels are short due to the high reactivity of NO with several species abundantly available in most biological environments. In mitochondria, these species include heme irons, O 2 Ϫ , and thiols. Thus the different cardiac NOSs localized at specific parts of the myocytes allow the NO produced within these parts to interact coordinately and restrictedly with the colocalized effectors.
In cardiac myocytes, eNOS is localized at the caveolae of the sarcolemma and T tubules, where it is associated with the scaffolding protein caveolin-3, the myocyte-specific structural protein of caveolae (46, 64) . The colocalization of eNOS with ␤-adrenergic receptors and Ca 2ϩ channels allows eNOS-gen- erated NO to remain within diffusion distance of its molecular targets (9) . Expression of eNOS in the myocardium is not limited to the cardiac myocytes. This NOS isoform is also expressed in endothelial cells (103) where NO exerts a pivotal role in the regulation of vascular tone. nNOS is localized at the SR, and under physiological conditions, it coimmunoprecipitates with ryanodine receptor. It also contributes to the regulation of myocardial function mainly by influencing myocyte Ca 2ϩ handling (9, 137) . nNOS-generated NO readily activates ryanodine receptor to release Ca 2ϩ from the SR. Such Ca 2ϩ release causes a positive inotropic effect, thus mediating an action on myocardial contractile function, i.e., the positive inotropism that seems to be opposite to that of eNOS (9) . iNOS, although not constitutively expressed in the myocardium, has been detected in heart tissues from patients with heart failure (37, 65) . There is a general consensus that iNOS is transiently expressed in the heart during immune responses under stress (8) and, therefore, during pathophysiological conditions of the myocardium such as in ischemia-reperfusion injury (133) , septicemia (125), heart failure (146), as well as during aging (138) . During the last fifteen years, different groups have used various experimental approaches and reported the presence of mtNOS in the heart (1, 10, 16, 40, 45, 60, 66, 72, 79, 91, 115, 129, 130, 140, 141, 143, 147) . Regarding the localization of mtNOS, one interesting study provided evidence about the docking of eNOS to the outer mitochondrial membrane in endothelial cells (52) . Mutant eNOS lacking a pentabasic amino acid sequence within the autoinhibitory domain showed dramatically reduced binding to the mitochondrial membrane, which was associated with increased oxygen consumption. On the other hand, a recent study showed the presence of angiotensin II type-2 receptors in inner mitochondrial membrane. They detected a NO response in isolated mitochondria associated to impaired O 2 consumption (1). Strategic localization of mtNOS in organelles that are in charge of cellular energy metabolism in high energy-utilizing cells such as cardiomyocytes indicates a pivotal control of processes whereby mitochondria play essential roles. Moreover, a spatially restricted intracellular localization of NO within mitochondria permits regulation of NOS activity by the local environment within individual organelles. Such reciprocal interaction between heart mitochondria and heart mtNOS might provide a unique distinction between mtNOS and non-mitochondrial NOS isoforms. Nevertheless, conflicting results have appeared in the literature during the last years, and the current view about heart mtNOS identity and relevance is incomplete.
Mitochondrial NOS. An immunohistochemical study used silver immunogold labeling method to stain heart, skeletal muscle, and kidney mitochondria and showed that about 85% of the heart mitochondria were positive for the eNOS label (10) . This report postulated that eNOS located in mitochondria could exert a ubiquitous regulation of oxidative phosphorylation. Later, two groups almost simultaneously proved the existence of a functional mtNOS in rat liver mitochondria localized at the inner mitochondrial membrane (54, 58) . Since then, the presence of NO in the mitochondria has been demonstrated by using several methods. Confocal microscopy using fluorescent probes for coupled mitochondria (MitoTracker) and NO (4,5-diaminofluorescein diacetate) indicated the presence of NO in mitochondria (87) . Also, direct evidence of mitochondrial NO production in endothelial cells was provided with similar experimental approaches (20, 38, 41) . Technical limitations of the methods used to detect NO in biological environments, such as the lack of specificity of fluorescent probes, include those used for detection of NO in mitochondria. Other studies have detected heart mitochondrial NO release using a direct spin trapping technique with electron paramagnetic resonance spectrometry (58, 66) . Additionally, NO concentration within mitochondria, which results from its production and consumption by mitochondria, has been estimated to be in the nanomolar range (17) . Heart mtNOS has been studied by functional experiments in which mitochondrial membrane potential-dependent NO production was measured in imaging experiments following permeabilization of cardiomyocytes (40) (Fig. 2A) or directly detected from isolated cardiac mitochondria (72, 143) (Fig. 2C) . Studies of cardiac mtNOS have used various methods including immunohistochemistry (10, 66) , spectrophotometry (16, 30, 45, 79, 115, 141, 142) , radiometry (139, 143) , fluorometry (40, 139, 143, 147) , chemiluminescence (143) , and electrochemistry (72) . On the other hand, one study reported that the ubiquinone/cyt bc 1 is a site where nitrite is reduced to form NO congeners within mitochondria in a NOS-independent manner (100). Despite the conflicting evidence about mtNOS (21, 81) , some authors concur on that heart mtNOS is relevant in physiological and pathological functions of heart mitochondria, with implications in ischemia-reperfusion injury and right ventricle hypertrophy (67, 96) .
The short mitochondrial genome encodes for only few proteins, none of which resembles cytoplasmic NOS. Therefore, if mtNOS is one of the cytoplasmic NOS isoforms, one of the nuclear-encoded NOS isoforms should be transported to the mitochondria after the protein is synthesized in the cytosol. All three NOS isoforms have been proposed to be located within mitochondria of different cells. In the heart, however, the most convincing data implicate nNOS as the primary candidate for the cytoplasmic NOS izosyme targeted into mitochondria (40, 72, 142) . Evidence in favor of eNOS (10, 66, 140) and iNOS (45, 60, 79, 129) (Fig. 2B ) presence in heart mitochondria has also been published. One study purified and analyzed mtNOS from rat liver by using matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF). The sequence of the purified protein was reported as the ␣-splice variant of the nNOS with acylation with myristic acid at the NH 2 -terminal and phosphorylation at the COOH-terminal region (44) . This report was not confirmed by others by using seven different NOS antibodies, and it was concluded that NOS is absent in mitochondria (81) . Another study showed a NOS activity in mouse cardiac mitochondria by measuring the NO production of an individual mitochondrion with a porphyrinic microsensor placed at the cytoplasmic face of the mitochondrial outer membrane. The sensor detected NO upon addition of Ca 2ϩ to the reaction medium containing mitochondria isolated from control mice. The NO signal was detected for mitochondria isolated from eNOS Ϫ/Ϫ or iNOS Ϫ/Ϫ animals, whereas no signal was detected in mitochondria from nNOS Ϫ/Ϫ mice (72) (Fig. 2C) . From nNOS alternative-splice variants currently described (111) , only the nNOS␣ is knocked out in nNOS Ϫ/Ϫ mice by deleting the exon 2 near the NH 2 -terminus. Nevertheless, the exact nature of heart mtNOS isoform is still not elucidated, a situation that extends to other reported mtNOS activities (10, 50, 66, 81). The 51 to 57% homology reported for nNOS, iNOS, and eNOS and the cross-reactivity of isoform-specific anti-NOS antibodies could provide an explanation for the incompatible results (73) . Moreover, mitochondrial preparations were shown to contain numerous proteins across a wide range of molecular weights that can react with anti-NOS antibodies (21) .
Regulation of NO production within mitochondria. Figure 3 shows that localization of NO production within mitochondria provides a distinct specific reciprocal regulation between mtNOS and intramitochondrial Ca 2ϩ , pH, L-arginine, O 2 , or redox state (36) . Indeed, heart mtNOS activity is dependent on cation concentration in the reaction medium. Extramitochondrial free Mg 2ϩ , a well-known mitochondrial Ca 2ϩ uniporter blocker, inhibits NO production in rat heart mitochondria by 60% in a dose-dependent manner (91, 143) . This concept is in agreement with other reports (40, 41) showing that blocking the mitochondrial Ca 2ϩ uniporter with ruthenium red inhibits mitochondrial NO production. In intact energized mitochondria, elevation of extramitochondrial Ca 2ϩ is sufficient to stimulate mtNOS activity and to decrease the respiration rate. Interestingly, substrate-energized heart mitochondria produce NO without additional supplementation with Ca 2ϩ (128) , indicating that the concentration of Ca 2ϩ in the mitochondrial preparation may be sufficient to sustain a basal mtNOS activity. Nevertheless, the functional studies performed on cardiac mitochondria isolated from mice (70, 72) or rats (91, 115, 126, 140, 141, 143) demonstrated the activation of mitochondrial NO production upon addition of Ca 2ϩ to the reaction medium. Taking into account that heart mitochondrial matrix Ca 2ϩ concentrations differ from cytosolic Ca 2ϩ concentrations (39, 85) , the existence of a Ca 2ϩ -dependent NOS within mitochondria has significant consequences in terms of the differential regulation of this enzyme.
Mitochondrial NO production is influenced by mitochondrial metabolic state (17, 126, 128) . During the transition from resting (state 4) to active (state 3) respiration, heart mitochondrial NO release decreases markedly (about 60%), from 2.2. to 1.2 nmol NO/min·mg protein (126) . Interestingly, the rate of NO release by isolated heart mitochondria at state 4 represents about 10% of the corresponding O 2 consumption, whereas at state 3 the rate of NO release represents only about 1.5% of O 2 uptake (17, 128) . This is consistent with the hypothesis that mitochondrial respiration at physiological O 2 levels is more sensitive to exogenous NO in state 3 than in state 4 (23) . To note, the fact that intact mitochondria produce NO at an estimated rate of about 1.2-2.2 nmol NO/min·mg protein leads to the notion that the NO concentration resulting from this production should be in the micromolar range. However, the estimated steady-state concentration of NO within mitochondria has been reported to remain in the nanomolar range (17) . This latter datum indicates that a substantial fraction of the NO produced in mitochondria reacts with mitochondrial targets such as O 2 Ϫ , heme groups, and thiols. In addition, heart mitochondrial NO release shows a strong and exponential dependence on the mitochondrial transmembrane potential (⌬) (17, 128) . This dependence is more pronounced in the physiological range of ⌬, that is between 150 and 180 mV, where small changes in the ⌬ cause noticeable variations in mitochondrial NO release. In addition, a marked decrease of mtNOS activity has been observed when ⌬ was collapsed by an uncoupler. To date, several studies have shown that abolishing ⌬ inhibits mtNOS activity, indicating a tight regulatory interplay between mitochondrial NO production and ⌬ (41, 72, 143) .
The mtNOS, same as cytoplasmic NOS isoforms, requires O 2 , L-arginine, and certain cofactors to produce NO. The apparent O 2 K m for heart mtNOS is 40 M (3), suggesting that under physiological conditions whereby O 2 concentration is in the 5-20 M range (28, 59 ) the mtNOS activity is oxygen limited. In this way, the in vivo enzymatic activity of heart mtNOS might be 6 -25% of its maximal activity (18) .
The study of NO production by heart mitochondrial membranes as a function of L-arginine concentration showed a hyperbolic response, with an apparent K m value of about 35 M, a concentration that is well within the estimated liver mitochondrial L-arginine levels of 150 -300 M (3, 128). However, rather lower intracellular levels of L-arginine were reported in cardiomyocytes (42) . Moreover, the expression of arginase II in mitochondria of mouse cardiac myocytes (122) and arginase I in feline cardiac myocytes (69) has been demonstrated. The activity of mtNOS may be impaired under the conditions whereby L-arginine concentration within the heart mitochondria is diminished.
Role of NO in the Regulation of Heart Function
The influence of NO on myocardium varies greatly depending on determinants including the NOS isoform activated, the rate of NO production, the signaling pathway triggered, and the redox environment within the site of NO production. Therefore, it is not surprising that paradoxical results exist about both positive and negative effects of NO and its related congeners in the heart (145). As described above, the specificity of NO regulation in the heart is conferred through spatial localization of NOSs to distinct signaling microdomains (9) . Thus eNOS is enriched in caveolar and T-tubular structures close to the diads, nNOS is found at SR membranes close to ion channels, and mtNOS is located in mitochondria close to the energy transduction and O 2 Ϫ production machinery. NO influences myocardial contractility, ventricular relaxation, mitochondrial respiration, and energy production through the distinct mechanisms discussed earlier in this review, and its concentration fluctuates within the cardiac cycle (107) .
The presence of NOS in cardiac mitochondria provides a mechanism of fine regulation of the respiratory complexes and enzymes of the citric acid cycle (Fig. 3) . Many studies indicate that mitochondrial NO regulates energy metabolism (94, 109) and inhibits cytochrome oxidase (4, 24, 26) . In studies with muscle and isolated beating heart, NO donors and agonists such as bradykinin suppress tissue O 2 uptake and H 2 O 2 production (136) . Moreover, it has been reported that NO increases oxidative phosphorylation efficiency (27) and regulates mitochondrial matrix pH, ⌬, and Ca 2ϩ buffering capacity (55). Thus NO not only regulates muscular contraction that is the major energy consuming process of the heart but also diminishes mitochondrial energy production (116) . In addition, mitochondria are major sources of reactive oxygen species such as O 2 Ϫ and H 2 O 2 (15) . Through its interaction with components of the electron transport chain, NO functions not only as a physiological inhibitor of cell respiration but also enhances the generation of reactive species (108) derived from the incomplete reduction of O 2 by mitochondria and thereby triggers various mechanisms underlying the survival or death of the cells (94) .
Functional relevance of mtNOS in heart physiology and pathology. The relevance of mtNOS in mitochondrial bioenergetics and cell physiology has been the subject of many studies. Pivotal roles of mtNOS have been postulated in chronic hypoxia, ischemia-reperfusion, cell signaling, aging, dystrophin deficiency, inflammation, and cancer. The mtNOS activity has been found upregulated in cold acclimation (105) . Treatment with enalapril, an angiotensin-converting enzyme inhibitor, produced an increase in the production of NO by heart mitochondrial membranes (16, 30) . Lately, a receptor for angiotensin was found located in inner mitochondrial membrane, and it was suggested that the renin-angiotensin system directly regulates mitochondrial NO production (1). In addition, heart mtNOS activity was increased in experimental endotoxemia after LPS treatment (3) . Therefore, a variety of physiological, pathological, and pharmacological situations can cause changes in heart mtNOS activity or expression. Figure 3 depicts distinct effects of NO on mitochondria, such as competitive inhibition of respiration (4, 24, 26, 108, 109) , regulation of the rate of production of species derived from O 2 partial reduction (108), as well as prevention or activation of mitochondrial permeability transition pore (mPTP) (31, 40, 84, 131) , and participation in Ca 2ϩ homeostasis (40) . Interestingly, the reversible inhibition of O 2 consumption shows a dependence on both O 2 and NO concentrations, competition between O 2 and NO, and different effects of NO in different mitochondrial metabolic states (4, 5) . Additionally, NO inhibits the electron transfer chain in the cytochromes b-c segment in complex III (108, 109) by possibly binding to iron-sulfur centers that are intermediates of electron transfers. This reaction increases the level of the semiquinone of ubiquinol that upon autoxidation reduces O 2 to O 2 Ϫ . Moreover, complex I is a target for reversible inhibition by Snitrosation of critical thiol residues, because its inhibition by NO can be reversed by light or reagents containing thiol groups (14) . These findings are in accordance with the structural and functional interaction observed among complexes I and IV and mtNOS (49, 106) . A physical proximity of mtNOS with the COOH-terminal peptide of the Va subunit of cytochrome c oxidase was shown by electron microscopic immunolocalization and coimmunoprecipitation studies. Other report showed that not only complex IV but also complex I proteins immunoprecipitate with intramitochondrial and translocated nNOS, which indicates a direct molecular interaction between mtNOS and complexes I and IV (49, 106) .
The ability of mtNOS to regulate mitochondrial O 2 uptake and H 2 O 2 production through the interaction of NO with the respiratory chain has been named mtNOS functional activity (16, 127) . This functional activity is determined by the difference in the rates of O 2 uptake or H 2 O 2 production in isolated mitochondria in two conditions. Under the condition when NO steady-state levels are the highest, such as in the presence of sufficient L-arginine and SOD, mitochondrial active O 2 consumption is impaired and mitochondrial H 2 O 2 production is enhanced. On the contrary, when NO steady-state levels are the lowest, mitochondrial active O 2 consumption is increased and mitochondrial H 2 O 2 production is decreased (127) . Such situation is achieved in the absence of NOS substrates or cofactors or in the presence of a NOS inhibitor or a NOS scavenger, e.g., oxyhemoglobin. Changes in mtNOS functional activity reveal modifications of NO production by mtNOS. For instance, treatment with enalapril produces a marked increase in mitochondrial NO production associated with an enhancement in mtNOS functional activity, as measured through both the O 2 uptake and H 2 O 2 production (16, 127) .
Some reports have established important functional implications of mtNOS activity (19, 40, 55, 56) . Those studies have shown that loading mitochondria with Ca 2ϩ decreases matrix pH in a N -monomethyl-L-arginine-sensitive manner (2). This acidification was related to a decrease in the proton extrusion from the matrix to the intermembrane space and a drop in the ⌬, a consequence of the inhibition of the respiratory chain. Moreover, it has been suggested that Ca 2ϩ uptake by respiring mitochondria stimulates mtNOS, elevates ONOO Ϫ formation, which in turn causes specific Ca 2ϩ release from mitochondria followed by mtNOS inactivation (2) . Evidence for ONOO Ϫ formation by mtNOS was originally observed in rat liver mitochondria (19, 56) . It was demonstrated that mtNOS-mediated ONOO Ϫ formation promoted Ca 2ϩ (19) and cytochrome c (56, 57) release from mitochondria, leading to a Bcl-2-dependent apoptosis. Moreover, exogenous and endogenously produced NO reduces mitochondrial Ca 2ϩ accumulation (38), providing a means by which mtNOS can influence mitochondrial metabolism as well as survival. In this way, NO generated within mitochondria regulates matrix pH, ⌬, and Ca 2ϩ buffering capacity. Such a wide spectrum of actions indicates that the interaction of NO and mitochondria plays critical roles in heart homeostasis.
HEART CHRONIC HYPOXIA. Adaptation to chronic hypoxia has been shown to confer the heart an improved tolerance to all major deleterious consequences of acute O 2 deprivation, resulting in cardioprotection, in a similar way to preconditioning (98) . NO has been extensively proposed as one of the molecular messengers involved in this type of adaptation (6) . However, the subcellular localization and the identity of the NOS implicated in the increased tolerance to ischemic injury remains to be fully established. Different groups have reported iNOS upregulation during the exposition of rats to chronic hypoxia (62, 114) . Some reports indicate that eNOS is upregulated during rabbit (47) and rat (48) heart adaptation.
Studies performed on mitochondrial fractions indicate that chronic hypoxia upregulates mtNOS. Rats submitted to simulated chronic hypoxia using a hypobaric chamber showed right ventricle hypertrophy, increased hematocrit values (78) , and about 60% enhanced activity of heart mtNOS (141). This upregulation was associated with a preservation of the papillary muscle contractile parameters upon aging and improved tolerance to postischemic contractile dysfunction. Using a similar approach, a decrease in heart mtNOS activity and expression during the regression of the cardioprotection conferred by hypoxia has been reported (79) . Other studies showed that liver mtNOS activity is upregulated after acute exposure to hypoxia (80, 118) .
These data are in agreement with the results obtained using a natural high altitude model, where rat heart mtNOS activity and expression were increased after 42-84 days of exposure (60, 142) . Rats submitted to high altitude also showed right ventricle hypertrophy. The enhancement in heart mtNOS activity showed a pattern similar to the one observed for hematocrit (142) . The effect was selective for heart mtNOS because the activities of liver mtNOS, nonmitochondrial heart NOS, and heart mitochondrial complexes were unchanged (60) .
These models of heart mtNOS upregulation in chronic hypoxia are relevant to chronic myocardial hypoxia involved in human coronary diseases. The increase in mitochondrial NO release, which decreases the consumption of O 2 by the respiratory chain, allows O 2 to diffuse further and to reach more mitochondria (86, 109) , providing a way of increasing O 2 extraction by the tissues. There is an increased requirement for energy during chronic exposure to hypoxia when O 2 availability is low. Additional changes in cardiomyocyte to satisfy the energy demands of the cell include an increase in the number of mitochondria, more homogenous distribution of the organelles, and a decrease in the mitochondrial size (29, 101) . NO triggers mitochondrial biogenesis in several cell types and tissues, including those obtained from the heart, through a cGMP-dependent mechanism (99) . The enhanced mitochondrial generation of reactive oxygen species constitutes another event implicated in the onset of cardioprotection (11) . One postulated mechanism whereby O 2 Ϫ and H 2 O 2 may be distinguished as prominent mediators of adaptation to hypoxia involves the stabilization of transcription factor hypoxia-inducible factor-1␣ (11) . Thus the NO produced by mtNOS may also act at this stage of the sequence of events as a building block implicated in the construction of the cardioprotection established during adaptation to chronic hypoxia.
HEART ISCHEMIA/HYPOXIA AND REPERFUSION. Acute myocardial ischemia/hypoxia can result in myocyte dysfunction and death. Therefore, restoration of the blood flow seems to be essential to prevent cell damage. However, the reoxygenation of the hypoxic myocytes is one of the prime mechanisms underlying cell and tissue damage in pathological conditions including ischemic heart disease (61) . A common feature of reperfusion is the increase in Ca 2ϩ concentration. NO has been indicated as one of the key factors involved in the onset of cell damage in ischemia/hypoxia and reperfusion (13) . Moreover, increased levels of oxidative species have been found under conditions associated with ischemia/hypoxia and reperfusion (25b). Pathological, i.e., excessive, levels of NO are likely to affect respiration by mechanisms qualitatively different from those observed during reversible physiological regulation. Increased ONOO Ϫ , together with mitochondrial malfunctioning, is a hallmark of hypoxia-reperfusion injury in the heart (130).
MtNOS-derived ONOO
Ϫ causes oxidative modification of mitochondrial components and releases the key mitochondrial proapoptotic protein, cytochrome c (56, 97) . Thus these organelles play a crucial role in oxidative injury during ischemia/ hypoxia and reperfusion (113, 136) . An in vitro model that allows studying isolated mitochondria under hypoxia or hypoxia-reoxygenation showed that mitochondria, independent of other cellular components, respond to hypoxia-reoxygenation primarily by increasing the intramitochondrial Ca 2ϩ levels through a shift in the balance between ionized and nonionized mitochondrial Ca 2ϩ in favor of the ionized form (143) . The mitochondrial production of NO is reduced during ischemia because NOS requires O 2 to generate NO and that low intracellular pH generated during ischemia inhibits the enzyme. During reperfusion, mtNOS produces a burst of NO, which results in the formation of ONOO Ϫ . This latter damages proteins and suppresses O 2 consumption in the postischemic myocardium. Furthermore, elevated intramitochondrial ionized Ca 2ϩ stimulates mtNOS and increases the mitochondrial production of O 2 Ϫ and ONOO Ϫ , leading to oxidative and nitrative modifications of mitochondrial proteins, release of cytochrome c from mitochondria, oxidative modification of mitochondrial lipids and proteins, and inactivation of mitochondrial enzymes susceptible to ONOO Ϫ (143). In contrast, ONOO Ϫ has been reported as beneficial in a concentration-dependent manner in blood-perfused hearts exposed to hypoxia/reoxygenation (89) .
At NO levels such as those reached during ischemia-reperfusion of cardiomyocytes, a reduction of ⌬ is produced with the subsequent reduction of Ca 2ϩ accumulation, thus protecting the cells from potentially lethal mitochondrial Ca 2ϩ overload (88, 113) . The cell injury and death observed after reoxygenation of the tissue are in accordance with several reports showing that NO can prevent or accelerate mPTP (31) . This depends on whether NO concentrations are physiological or supraphysiological and whether O 2 Ϫ is generated simultaneously (40) . While supraphysiological NO concentrations sensitize mPTP, physiological levels of NO inhibit mPTP opening with an IC 50 of about 10 nM (22) . The mPTP opens in response to high matrix Ca 2ϩ concentrations, low ATP levels, and enhanced O 2 Ϫ production (90). Opening of the pore causes abrupt mitochondrial depolarization, ATP depletion, and necrotic or apoptotic cell death (12) . In this regard, heart and liver mtNOS play important roles in mPTP regulation (40, 84, 147) , suggesting relevance of mtNOS for yet another important mitochondrial function. On the other hand, the existence of alternative NOS-independent mechanisms of NO production that may operate in situations in which conventional NO production is impaired has been described (132) . Inorganic nitrite (NO 2 Ϫ ) can be chemically reduced back to NO in acidic media. During global ischemia, the pH in the heart falls to around 5.5, a condition that greatly accelerates reduction of NO 2 Ϫ to NO (148) . Finally, it has been suggested that a transient reversible inhibition of the mitochondrial electron transfer minimizes ischemia-reperfusion injury and that blockade of electron transport at complex I preserves respiration during reperfusion (95) . Studies have shown that complex I inhibition by nitrosation protects mitochondria during hypoxia and reoxygenation and cardiomyocytes during ischemia-reperfusion (25a, 119). There is evidence that S-nitrosation of complex I proteins is associated with cytoprotection from the damage caused by ischemia-reperfusion (43, 110) .
Conclusions and Perspectives
NO is a molecule of central importance for the regulation of heart function and involved in a broad array of key processes in cardiac metabolism. Different NOSs exist in different localizations within the cardiac cells and exert a particular influence in cardiac function. The present article reviewed some of the current knowledge about NO metabolism in the heart with an emphasis on heart mtNOS, summarizing both the evidence provided by the published studies and the controversies that still surround this enzyme. Certainly, further studies are required in this field for reaching a consensus. The regulation of mtNOS by ⌬ and Ca 2ϩ allows the enzyme to respond to changes in cardiomyocyte energy homeostasis. Moreover, alterations of mtNOS activity and expression during chronic hypoxia and ischemia-reperfusion support the relevance of this enzyme in long-term heart adaptation to decreased O 2 or in acute ischemic insult. At the same time, NO generated within mitochondria has focused effects on mitochondrial function. Together, heart mtNOS allows NO to optimize the balance between cardiac energy production and utilization and to regulate processes such as apoptosis, oxygen, and nitrogen free radical production and Ca 2ϩ homeostasis. 
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